Boehringer Ingelheim Pharmaceuticals, Inc. Announces Launch of GLORIA(TM)-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation

RIDGEFIELD, Conn., May 3, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the launch of the GLORIA-AF Registry Program, the largest prospective observational study in n…
Read the full story: BioSpace.com Featured News